Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis
Bolt, J.W.; van Kuijk, A.W.; Teunissen, M.B.M.; van der Coelen, D.; Aarrass, S.; Gerlag, D.M.; Tak, P.P.; van de Sande, M.G.; Lebre, M.C.; van Baarsen, L.G.M. Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis. Biomedicines 2022, 10, 324. https://doi.org/10.3390/biomedicines10020324
Bolt JW, van Kuijk AW, Teunissen MBM, van der Coelen D, Aarrass S, Gerlag DM, Tak PP, van de Sande MG, Lebre MC, van Baarsen LGM. Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis. Biomedicines. 2022; 10(2):324. https://doi.org/10.3390/biomedicines10020324
Chicago/Turabian StyleBolt, Janne W., Arno W. van Kuijk, Marcel B.M. Teunissen, Dennis van der Coelen, Saïda Aarrass, Daniëlle M. Gerlag, Paul P. Tak, Marleen G. van de Sande, Maria C. Lebre, and Lisa G.M. van Baarsen. 2022. "Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis" Biomedicines 10, no. 2: 324. https://doi.org/10.3390/biomedicines10020324